Company / Depreciation & Amortization
Ligand Pharmaceuticals, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$33.8M
FY2025
5-year range
$33.8M / $51.5M
FY2021-FY2025
Trend
-4.2%
vs FY2024
Sector context
#36 of 168
Health Care
What the data says
Ligand Pharmaceuticals, Inc.'s depreciation & amortization of $34M is higher than 79% of companies in the Health Care sector (FY2025). Depreciation & Amortization has declined for 3 consecutive years, from $52M in FY2022 to $34M in FY2025.
Based on SEC 10-K filings.
$34M in FY2025 with a 5-year CAGR of +5.6%. Top quartile in the Health Care sector.
Improved from $37M to $34M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -13.1%
- 5-Year CAGR
- +5.6%
- 10-Year CAGR
- -
Sector benchmark
-84.1% below sector average
Key checks
Key Insights
- Ligand Pharmaceuticals, Inc.'s depreciation & amortization has declined for 3 consecutive years.
- 5-year CAGR of +5.6%, indicating consistent growth.
- In FY2025, depreciation & amortization decreased 4.2% year-over-year.
- Ranks #36 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $33.8M | -4.2% |
| FY2024 | $35.2M | -3.5% |
| FY2023 | $36.5M | -29.1% |
| FY2022 | $51.5M | +0.9% |
| FY2021 | $51.1M | +98.8% |
| FY2020 | $25.7M | +39.9% |
| FY2019 | $18.4M | +43.6% |
| FY2018 | $12.8M | +16.7% |
| FY2017 | $11.0M | -3.0% |
| FY2016 | $11.3M | +329.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026